Proficiency Testing schemes - Results from 2016 & 2017

Proficiency Testing schemes - Results from 2016 & 2017

• 1.
  Proficiency Testing Schemes; Results from2016 & 2017 Anna Lüdi, Ginette Wilsden, Clare Browning, Hannah Baker, Valerie Mioulet, Britta Wood, Ashley Gray, Lissie Henry, Jemma Wadsworth, Julie Maryan, Sarah Belgrave, Donald King FMD and SVD Reference Laboratories
• 2.
  To assist NationalFMD Laboratories to develop/improve accurate and reproducible FMD diagnostic tests  Achieved by feedback, training and consultation Quality Assurance requirements to support ISO/IEC 17025 Harmonisation amongst laboratories  Achieved by presenting results on how reference laboratories compare, distribution of reagents and protocols Purpose of Proficiency Testing Scheme (PTS)
• 3.
  3 panels forFMDV Panel 1 – outbreak scenario Panel 2 – can your diagnostic assay detect the latest strains? Panel 3 – serology Panel 3a - outbreak scenario Panel 3b - QA Quality Assurance Virology - all strains are isolated from field strains and sequenced Serology - all sera are from experimental studies 10x testing has occurred for all diagnostic test types The Scheme NOTE – Swine Vesicular Disease Virus samples/panels will not be discussed
• 4.
  Participants in 2016and 2017 74 countries in total
• 5.
  Supplied as infectiousand non-infectious specimens Based on the scenarios provided (Panel 1a-b), use your national contingency plan or similar document to identify the appropriate tests and testing sequence. Please provide a flow chart in English to show the testing and decision tree adopted for evaluating these samples (the original contingency plan is not necessary). This panel is primarily intended to evaluate your overall diagnostic procedure and interpretation of these suspect cases, rather than focussing on the performance of individual test methods. Therefore, it may not be necessary to use all of your assays to test these samples. If downstream characterisation methods, (such as viral sequencing) are part of your contingency plan, please use and report the results of these assays. Panel 1 Outbreak scenarios of vesicular diseases Tests used – Virus Isolation, Antigen ELISA, rRT-PCR and sequence
• 6.
  Continued improvement –2017 PTS all correct results for virus isolation, rRT-PCR and antigen ELISA Panel 1 Take home messages
• 7.
  Supplied as non-infectious Thispanel of viruses represents recent FMDV isolates that pose a current threat to the EU and elsewhere. The aim of the evaluation is to make sure these latest strains can be detected. Please use appropriate methods to test these virological samples. Note that some of these samples may not contain viruses. Panel 2 Quality assurance to ensure recent FMDV strains are detected Tests used – Antigen ELISA and rRT-PCR
• 8.
  FMD-free (without vaccination) Sporadic Endemic Pool1 Pool 2 Pool 3 Pool 5 Panel 2 Strains Selected Strain Lineage O/MOR/1/2015 O/ME-SA/Ind-2001d A/PAK/12/2015 A/ASIA/Iran-05FAR-11 Asia 1/TUR/12/2015 Asia 1/ASIA/Sindh-08 O/EGY/18/2016 O/EA-3 A/IRN/8/2016 A/ASIA/G-VII SAT 2/OMN/4/2015 SAT 2/VIIAlx-12 20162017
• 9.
  To Consider What strainsand lineages are endemic in your area? What is the risk from surrounding pools? FMD-free (without vaccination) Sporadic Endemic Pool 1 Pool 2 Pool 3 Pool 5
• 10.
  To Consider What strainsand lineages are endemic in your area? What is the risk from surrounding pools? FMD-free (without vaccination) Sporadic Endemic Pool 1 Pool 2 Pool 3 Pool 5
• 11.
  Continued Improvements  Theantigen ELISA shows less cross-reactivity than in the past  More laboratories are determining serotypes as PanFMD rather than negative  For 2017 all laboratories correctly identified FMDV samples as FMDV  However, four laboratories incorrectly identified a negative sample as inconclusive/positive Overall Conclusions
• 12.
  Panel 3 –FMDV serology ELISAs being used 0 10 20 30 40 50 60 70 62 24 18 16 14 11 5
• 13.
  Panel 3 –FMDV serology Non-structural protein ELISAs being used 0 10 20 30 40 50 42 20 8 6 3 2
• 14.
  Panel 3a Continuation ofoutbreak scenarios During the outbreak described in scenario 1 (Panels 1a and b), some animals were vaccinated with a high potency, purified monovalent vaccine. Three sera have been collected after vaccination from farms within the 10km surveillance zone surrounding the outbreaks. Please test them and define whether the samples are from infected animals, and if not, whether or not there is any evidence of vaccine-induced immunity. Note you should use information from Panels 1a and b to limit the range of testing that you need to carry out.
• 15.
  Continued improvement –compared to 2016, more laboratories correctly chose the ELISA for serological testing Although individual serotypes were correctly identified for each assay, some laboratories included multiple serotypes in overall conclusions. Panel 3a Take home messages
• 16.
  Panel 3b QA Panel Youhave been asked to carry out post-vaccination monitoring for a country where FMD is endemic. Cattle have been vaccinated with serotype Asia 1 (Asia-1 Shamir) vaccine or A (A22) vaccine; however, there is concern that there may have been an outbreak in the area and the vaccination history is not clear. Please test the samples and comment as to whether the samples are from infected animals, and if not, whether or not there is any evidence of vaccine-induced immunity.
• 17.
  Continued improvement –for 2017 all laboratories correctly identified NSP-specific antibodies  However, four laboratories incorrectly identified a negative sample as inconclusive/positive Although individual serotypes were correctly identified for each assay, some laboratories included multiple serotypes in overall conclusions  Question of cross reactivity? Panel 3b Take home messages
• 18.
  O A C More on cross-reactivity Seeposter by Alison Morris O A C O A C 050100 050100 050100 050100 050100 050100 Partners: SAT1 SAT2 SAT3 Asia1 SAT1 SAT2 Asia1 SAT1 SAT2 SAT3 Asia1 SAT3
• 19.
  Acknowledgement World Reference Laboratory CentralService Unit Proficiency Testing Scheme Advisory Board for participating FMD and SVD Reference Laboratories Contact for PTS – [email protected]
• 20.
  2019 PTS andbeyond From January 1st 2019 the European Union PTS will be carried out by by anses and sciensano There is currently no budget for the FAO/self-funded PTS for 2019 However, final decisions have not yet been made Your feedback as participants would be useful to determine a way forward…